Drug Trial Radar · NCT01358435
Comparative Wockhardt's Glucose Clamp Study-Human Isophane Susp 30IU/ml/70IU/ml With Novolin70/30, in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
53
Actual
Start
Jan 2011
Primary completion
May 2011
Study completion May 2011
Sponsor
- Lead sponsor
- WockhardtIndustry
- Sponsor type
- Industry
- First posted
- May 23, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Health services research
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this trial is to demonstrate bioequivalence of Wosulin 70/30 to Novolin® 70/30 with regard to its total and to its maximum serum insulin concentrations.
Conditions
- Diabetes Mellitus
Interventions
30% Regular Insulin Human Neutral and 70%Isophane InsulinBiological
Total Dose per subject is 0.4 IU/Kg given subcutaneously.
Novolin 70/30Biological
Total Dose per subject is 0.4IU/Kg given Subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean AUC0-24h and CmaxTime frame: Visit 2 and 3
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institute for Clinical Research
Chula Vista, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.